The company's financial position has deteriorated significantly, with total assets contracting to $11.6 million and shareholders' equity falling to a negative $54.0 million as of 2025Q3.
| Metric | TTM | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 |
|---|
| Total Current Assets | 8.25M | 21.27M | 30.12M | 49.4M | 42.14M | 18.12M | 25.22M | 42.94M | 37.64M | 83.63M | 20.48M | 8.32M | 2.02M | 883K |
| Cash & Short-Term Investments | 6.8M | 20.02M | 28.92M | 48.42M | 30.44M | 17.29M | 22.59M | 40.88M | 37.64M | 83.63M | 20.28M | 8.27M | 1.91M | 856K |
| Cash Only | 6.8M | 20.02M | 28.92M | 48.42M | 30.44M | 17.29M | 22.59M | 8.04M | 9.22M | 34.82M | 20.28M | 8.27M | 1.91M | 856K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 32.84M | 28.42M | 48.81M | 0 | 0 | 0 | 0 |
| Accounts Receivable | 266K | 507K | 170K | 0 | 10M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | 85.71 | 111.21 | 7.54 | - | 123.42 | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 921K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 13K | 311K | 279K | 779K | 109K | 1.49M | 17K | 116K | 290K | 40K | 7K | 45K | 0 |
| Total Non-Current Assets | 3.39M | 3.85M | 3.89M | 1.9M | 767K | 1.2M | 1.56M | 1.18M | 360K | 360K | 573K | 1.98M | 120K | 65K |
| Property, Plant & Equipment | 3.36M | 3.82M | 3.87M | 1.87M | 607K | 944K | 1.2M | 790K | 885K | 94K | 156K | 205K | 98K | 50K |
| Fixed Asset Turnover | 0.93x | 0.44x | 2.13x | 0.71x | 48.72x | 8.36x | 1.82x | 0.04x | 0.39x | 5.53x | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 30K | 0 | 260K | 0 | 360K | 360K | 360K | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 30K | 30K | 30K | 0 | 160K | 0 | 360K | 26K | -885K | -94K | 417K | 1.77M | 22K | 15K |
| Total Assets | 11.64M | 25.13M | 34.02M | 51.3M | 42.9M | 19.32M | 26.78M | 44.12M | 40.49M | 84.81M | 21.05M | 10.3M | 2.14M | 948K |
| Asset Turnover | 0.19x | 0.07x | 0.24x | 0.03x | 0.69x | 0.41x | 0.08x | 0.00x | 0.01x | 0.01x | - | - | - | - |
| Asset Growth % | -192.04% | -26.14% | -33.69% | 19.58% | 122.04% | -27.84% | -39.31% | 8.96% | -52.26% | 302.82% | 104.44% | 381.94% | 125.42% | - |
| Total Current Liabilities | 2.77M | 4.79M | 6.81M | 5.78M | 4.64M | 9.94M | 10.9M | 10.48M | 13.52M | 5.41M | 5.2M | 2.42M | 683K | 531K |
| Accounts Payable | 796K | 1.45M | 2.21M | 1.05M | 941K | 2M | 1.28M | 6.87M | 5.38M | 2.59M | 1.47M | 1.26M | 248K | 0 |
| Days Payables Outstanding | 1K | 3.56K | 2.27K | 1.88K | - | - | - | - | - | - | 16.25K | - | - | - |
| Short-Term Debt | 0 | 0 | 364K | 349K | 0 | 991K | 1.33M | 556K | 3.2M | 0 | 1.73M | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 75K | 205K | 0 | 5M | 5M | 0 | 140K | 160K | 0 | 0 | 0 | 2K |
| Other Current Liabilities | 0 | 0 | 2.31M | 2.34M | 0 | 1.13M | 2.28M | 1.86M | 219K | 23K | 9K | 835K | 113K | 293K |
| Current Ratio | 2.98x | 4.44x | 4.42x | 8.54x | 9.08x | 1.82x | 2.31x | 4.10x | 2.78x | 15.46x | 3.94x | 3.43x | 2.95x | 1.66x |
| Quick Ratio | 2.98x | 4.44x | 4.42x | 8.54x | 8.88x | 1.82x | 2.31x | 4.10x | 2.78x | 15.46x | 3.94x | 3.43x | 2.95x | 1.66x |
| Cash Conversion Cycle | -918.04 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 62.82M | 59.19M | 43.12M | 34.91M | 288K | 616K | 4.72M | 10.02M | 8.01M | 7.59M | 52.52M | 27.09M | 12.19M | 178K |
| Long-Term Debt | 0 | 51.77M | 41.99M | 33.98M | 0 | 0 | 3.82M | 9.42M | 4.81M | 7.59M | 4.24M | 0 | 268K | 150K |
| Capital Lease Obligations | 783K | 328K | 649K | 936K | 288K | 616K | 897K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -750K | -320K | 47.32M | 0 | 0 | 0 |
| Other Non-Current Liabilities | 62.76M | 7.09M | 480K | 0 | 0 | 0 | 0 | 605K | 610K | 0 | 258K | 26.89M | 11.92M | 2K |
| Total Liabilities | 65.59M | 63.98M | 49.93M | 40.7M | 4.93M | 10.56M | 15.62M | 20.5M | 19.08M | 13.15M | 57.71M | 29.51M | 12.88M | 709K |
| Total Debt | 446K | 52.47M | 43M | 35.26M | 675K | 1.98M | 6.41M | 9.97M | 8.01M | 7.59M | 5.98M | 0 | 268K | 150K |
| Net Debt | -6.36M | 32.45M | 14.08M | -13.16M | -29.76M | -15.31M | -16.19M | 1.93M | -1.22M | -27.24M | -14.31M | -8.27M | -1.64M | -706K |
| Debt / Equity | -0.01x | - | - | 3.32x | 0.02x | 0.23x | 0.57x | 0.42x | 0.37x | 0.11x | - | - | - | 0.63x |
| Debt / EBITDA | -0.02x | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 0.28x | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -1.39x | -2.51x | -2.47x | -8.87x | - | -53.36x | -29.31x | - | - | - | -52.48x | -26.46x | -314.39x | - |
| Total Equity | -53.95M | -38.85M | -15.91M | 10.61M | 37.98M | 8.76M | 11.16M | 23.62M | 21.41M | 71.66M | -36.66M | -19.21M | -10.74M | 239K |
| Equity Growth % | -382.06% | -144.19% | -250.01% | -72.07% | 333.36% | -21.46% | -52.76% | 10.3% | -70.12% | 295.47% | -90.8% | -78.93% | -4592.89% | - |
| Book Value per Share | -10.31 | -7.90 | -3.86 | 2.64 | 9.51 | 2.83 | 4.38 | 11.53 | 12.69 | 81.98 | -44.80 | -23.48 | -107.21 | 0.04 |
| Total Shareholders' Equity | -53.95M | -38.85M | -15.91M | 10.61M | 37.98M | 8.76M | 11.16M | 23.62M | 21.41M | 71.66M | -36.66M | -19.21M | -10.74M | 239K |
| Common Stock | 78K | 77K | 63K | 61K | 60K | 52K | 44K | 32K | 25K | 25K | 3K | 4K | 3K | 2K |
| Retained Earnings | -373.96M | -355.27M | -320.92M | -288.44M | -255.49M | -255.87M | -237.66M | -206.89M | -124.22M | -65.25M | -39.36M | -21.72M | -11.54M | -4.28M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2.51M | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -8K | -13K | -103K | -55K | -22K | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Imminent liquidity and solvency risk
According to quarterly balance sheet data, total assets have plummeted from $40.1 million in 2025Q1 to just $11.6 million by 2025Q3, signaling a rapid contraction in the company's resource base as it continues to fund clinical development without sufficient offsetting revenue or capital inflows.
The consistent decline in total assets suggests that the company is consuming its primary liquidity buffers to sustain operations. This trajectory implies that the firm is approaching a critical juncture where the current asset mix may no longer support the ongoing clinical trial obligations.
Based on reported financial statements, the company's cash position has deteriorated significantly, falling from $35.4 million in 2024Q1 to a precarious $6.8 million as of 2025Q3, which severely limits the firm's ability to absorb further operational shocks or clinical trial delays.
While the current ratio remains at 2.98, this metric is misleading given the rapid depletion of cash and the absence of significant revenue-generating assets. Investors should monitor the cash burn rate closely, as the current liquidity profile suggests that the company may require external financing in the near term.
As indicated by the company's balance sheet, shareholders' equity has fallen deeper into negative territory, reaching -$54.0 million in 2025Q3, a trend driven by the persistent accumulation of losses that have completely eroded the company's book value over the last ten quarters.
The widening deficit in retained earnings reflects the high cost of clinical development and the lack of commercial scale. This negative equity position suggests that the company is effectively operating on borrowed time and capital, which may complicate future financing efforts or strategic partnerships.
Based on an analysis of the balance sheet, the company's reliance on debt instruments, which spiked to $54.1 million in 2025Q1 before being partially addressed, highlights a volatile capital structure that poses a significant risk to long-term solvency and shareholder value preservation.
The sudden fluctuations in debt levels suggest that the company has been forced to rely on opportunistic or high-cost financing to bridge its operational gaps. This reliance on debt, combined with a negative equity base, warrants further investigation into the terms of these obligations and their potential impact on future cash flows.
Quick answers to the most common questions about buying CLSD stock.
As of 2024, Clearside Biomedical, Inc. (CLSD) had total assets of $25.1M including $21.3M in current assets.
Clearside Biomedical, Inc. (CLSD) carries total debt of $52.5M, offset by $20.0M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Clearside Biomedical, Inc. (CLSD) has total shareholders' equity (book value) of $-38.9M ($-7.90 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Clearside Biomedical, Inc. (CLSD) reported a current ratio of 4.44x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.